How much funding has Enodia Therapeutics raised?

Enodia Therapeutics has raised $25.0M in total funding, most recently a Seed round.

Who are Enodia Therapeutics's investors?

Enodia Therapeutics's investors include Elaia, Pfizer Ventures, Bpifrance, Mission BioCapital.

When was Enodia Therapeutics founded?

Enodia Therapeutics was founded in 2025.

Where is Enodia Therapeutics headquartered?

Enodia Therapeutics is headquartered in Paris, France.

What industry is Enodia Therapeutics in?

Enodia Therapeutics operates in Biotech, Healthcare.

Enodia Therapeutics

A new approach for targeted protein degradation

Paris, France · Founded 2025 · $25.0M raised

Biotech

Healthcare

Headquarters: Paris
Founded: 2025
Business Model: B2B
Website: enodiatx.com

Total Funding: $25.0M
Last Round: $25.0M SeedJan 2026
Rounds: 1

About

Enodia Therapeutics is a French biotechnology company developing best-in-class small-molecule therapies that target the Sec61 translocon — a novel mechanism enabling degradation of disease-related proteins at the point of synthesis, before they exert pathological effects. Founded in 2025 and originating from foundational research at the Institut Pasteur under Prof. Caroline Demangel, the company was created and incubated by Argobio Studio. Enodia's initial therapeutic focus is inflammatory and autoimmune diseases, targeting previously undruggable secreted and membrane proteins. The company raised €20.7M in early 2026 to advance its targeted protein degradation platform.

Summary

Enodia Therapeutics is a Biotech company based in Paris, France, founded in 2025. It has raised $25.0M in total across 1 round, most recently a $25.0M Seed round in Jan 2026. Investors include Elaia, Pfizer Ventures and Bpifrance.